GYRE THERAPEUTICS: Kaskela Law Announces Investigation of Gyre Therapeutics, Inc. (GYRE) and Encourages Shareholders to Contact the Firm

PHILADELPHIA, April 20, 2026 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Gyre Therapeutics, Inc. (NASDAQ: GYRE) (“Gyre”) on behalf of the company’s investors.

The investigation seeks to determine whether Gyre and/or the company’s officers and directors violated the securities laws or breached their fiduciary duties in connection with recent corporate actions.

Gyre shareholders who would like to learn more about the investigation and their legal rights and options are encouraged to contact lead investigative attorney Adrienne Bell, Esq. at (484) 229 – 0750, by email at abell@kaskelalaw.com, or by filling out our online form at:

https://kaskelalaw.com/case/gyre-therapeutics/

ABOUT KASKELA LAW:

Kaskela Law exclusively represents investors in securities fraud, corporate governance, and merger & acquisition litigation on a contingent basis. For additional information about the firm, including our recent monetary recoveries for investors, please visit our website (www.kaskelalaw.com) or contact us today at (888) 715 – 1740.

KASKELA LAW LLC

D. Seamus Kaskela, Esquire

Adrienne Bell, Esquire

18 Campus Boulevard, Suite 100

Newtown Square, PA 19073

(484) 229 – 0750

www.kaskelalaw.com

This communication may constitute attorney advertising in certain jurisdictions.